Document is current

Article History

Received: 31 August 2018

Accepted: 13 March 2019

First Online: 28 March 2019

Ethics approval and consent to participate

: All patients provided written informed consent before enrolment. The study was performed in accordance with good clinical practices and Declaration of Helsinki guidelines. Approval from the appropriate ethics committees and institutional review boards was obtained and documented before the study. (Name of Ethics committee: Cancer Hospital, Chinese Academy of Medical Sciences, National GCP Center for Anticancer Drugs; Ethic approval letter ID: 11–95/530, Clinical Protocol ID: TG11141CR; Approval date: Nov. 24, 2011. This trial was registered with(NCT02496949).

: In addition to the consent form for the enrolment purpose, the signed consent forms also cover the agreement that the enrolled patients allow his/her data generated from this study to be published with blinded ID and privacy protection, regardless any format of presentation.

: Y F, B X, Funding from Chinese Academy of Medical Science (CAMS) Initiative for Innovative Medicine; S L and R H: Ex-employees of Beijing Shenogen Biomedical Ltd.; X D, J Y, J J, H Z, R H, W Q, K L, Y I, S W, L Z, Nothing to disclose; B Y, K M: Employee of Beijing Shenogen Biomedical Ltd.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.